$642 Million is the total value of Broadfin Capital, LLC's 51 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 160.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LJPC | Buy | LA JOLLA PHARMACEUTICAL CO | $49,337,000 | +48.9% | 1,656,720 | +60.9% | 7.69% | +41.9% |
| ADMS | New | ADAMAS PHARMACEUTICALS INC | $27,131,000 | – | 1,135,203 | +100.0% | 4.23% | – |
| ZGNX | Buy | ZOGENIX INC | $21,522,000 | +17.6% | 537,380 | +17.6% | 3.35% | +12.1% |
| GWPH | Buy | GW PHARMACEUTICALS PLCads | $19,721,000 | +21.5% | 175,030 | +42.4% | 3.07% | +15.8% |
| AVDL | Buy | AVADEL PHARMACEUTICALS PLCsponsored adr | $19,134,000 | -10.0% | 2,624,663 | +1.3% | 2.98% | -14.2% |
| NUVA | Buy | NUVASIVE INC | $13,485,000 | +180.8% | 258,292 | +214.6% | 2.10% | +167.6% |
| AMAG | New | AMAG PHARMACEUTICALS INC | $12,066,000 | – | 598,800 | +100.0% | 1.88% | – |
| KALA | New | KALA PHARMACEUTICALS INC | $10,784,000 | – | 681,239 | +100.0% | 1.68% | – |
| ATRS | Buy | ANTARES PHARMA INC | $10,281,000 | +13.9% | 4,673,247 | +3.0% | 1.60% | +8.6% |
| GKOS | New | GLAUKOS CORP | $9,061,000 | – | 293,900 | +100.0% | 1.41% | – |
| ANAB | New | ANAPTYSBIO INC | $8,243,000 | – | 79,200 | +100.0% | 1.28% | – |
| CI | New | CIGNA CORPORATION | $7,146,000 | – | 42,600 | +100.0% | 1.11% | – |
| MRK | New | MERCK & CO INC | $7,130,000 | – | 130,900 | +100.0% | 1.11% | – |
| SLGL | New | SOL GEL TECHNOLOGIES | $6,671,000 | – | 647,700 | +100.0% | 1.04% | – |
| VCEL | Buy | VERICEL CORP | $6,556,000 | +1289.0% | 658,900 | +661.2% | 1.02% | +1227.3% |
| ESPR | New | ESPERION THERAPEUTICS INC NE | $6,277,000 | – | 86,786 | +100.0% | 0.98% | – |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $6,257,000 | +35.6% | 2,078,799 | +80.7% | 0.98% | +29.3% |
| PRTK | Buy | PARATEK PHARMACEUTICALS INC | $6,209,000 | -14.6% | 477,607 | +17.6% | 0.97% | -18.6% |
| PCRX | New | PACIRA PHARMACEUTICALS INC | $5,186,000 | – | 166,500 | +100.0% | 0.81% | – |
| OXFD | New | OXFORD IMMUNOTEC GLOBAL PLC | $4,659,000 | – | 374,233 | +100.0% | 0.73% | – |
| PGNX | New | PROGENICS PHARMACEUTICALS INcall | $3,730,000 | – | 500,000 | +100.0% | 0.58% | – |
| VAR | New | VARIAN MED SYS INC | $3,680,000 | – | 30,000 | +100.0% | 0.57% | – |
| NVTA | New | INVITAE CORP | $3,518,000 | – | 750,000 | +100.0% | 0.55% | – |
| TTPH | Buy | TETRAPHASE PHARMACEUTICALS I | $3,219,000 | -42.5% | 1,048,642 | +17.9% | 0.50% | -45.2% |
| SCYX | New | SCYNEXIS INC | $2,527,000 | – | 1,885,904 | +100.0% | 0.39% | – |
| IVTY | New | INVUITY INC | $1,150,000 | – | 298,800 | +100.0% | 0.18% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Broadfin Healthcare Master Fund Ltd #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIODELIVERY SCIENCES INTL IN | 27 | Q4 2019 | 4.8% |
| HERON THERAPEUTICS INC | 24 | Q4 2019 | 9.0% |
| LA JOLLA PHARMACEUTICAL CO | 24 | Q4 2019 | 7.7% |
| RECRO PHARMA INC | 24 | Q4 2019 | 4.1% |
| ANTARES PHARMA INC | 24 | Q3 2019 | 3.4% |
| RETROPHIN INC | 23 | Q3 2019 | 7.0% |
| ARATANA THERAPEUTICS INC | 22 | Q2 2019 | 8.1% |
| MIRATI THERAPEUTICS INC | 22 | Q1 2019 | 7.9% |
| CATALYST PHARM PARTNERS INC | 22 | Q3 2019 | 6.2% |
| ANGIODYNAMICS INC | 21 | Q3 2018 | 6.6% |
View Broadfin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Eiger BioPharmaceuticals, Inc.Sold out | January 04, 2021 | 0 | 0.0% |
| LA JOLLA PHARMACEUTICAL COSold out | January 04, 2021 | 0 | 0.0% |
| STRATA Skin Sciences, Inc. | June 23, 2020 | 1,529,392 | 4.5% |
| Teligent, Inc.Sold out | February 25, 2020 | 0 | 0.0% |
| Neos Therapeutics, Inc.Sold out | February 14, 2020 | 0 | 0.0% |
| Aclaris Therapeutics, Inc. | February 13, 2020 | 1,888,039 | 4.6% |
| Adamas Pharmaceuticals IncSold out | February 13, 2020 | 0 | 0.0% |
| ADMA BIOLOGICS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
| AVADEL PHARMACEUTICALS PLC | February 13, 2020 | 1,029,012 | 2.8% |
| CATALYST PHARMACEUTICALS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
View Broadfin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-03-22 |
| 4 | 2022-02-15 |
| 4 | 2022-01-31 |
| 4 | 2021-11-22 |
| 4 | 2021-11-15 |
| 4 | 2021-11-09 |
| 4 | 2021-08-10 |
| 4 | 2021-05-13 |
| SC 13G/A | 2021-01-04 |
| SC 13G/A | 2021-01-04 |
View Broadfin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.